RegeneRx Biopharmaceuticals, Inc. (RGRX)
| Market Cap | 1.06K +249.7% |
| Revenue (ttm) | 76.76K -0.0% |
| Net Income | -1.69M |
| EPS | -1.18 |
| Shares Out | 1.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155 |
| Open | 0.0007 |
| Previous Close | 0.0007 |
| Day's Range | 0.0007 - 0.0007 |
| 52-Week Range | 0.0002 - 0.1730 |
| Beta | 173.81 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About RGRX
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tβ4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee’s Pharmaceutical Group for the development and marketing of Tβ4-related products; and HLB Therapeutics for the development and marketing of RGN-259, and RGN-137 f... [Read more]
News
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repa...
RegeneRx Receives Stockholder Approval for Reverse Stock Split
ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repai...
RegeneRx To Extend Consent Solicitation Vote
ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, a...
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259
ROCKVILLE, Md. , April 13, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repai...
RegeneRx Issues Letter To Stockholders
ROCKVILLE, Md. , April 11, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, r...
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy
ROCKVILLE, Md. , Jan. 31, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair...
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
ROCKVILLE, Md. , Jan. 3, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair,...
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease
Expect ARISE-4 Trial to Begin Around 2nd Quarter of 2023 ROCKVILLE, Md. , Oct. 24, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug...
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)
First of Two Phase 3 NK Trials Expected to Start in November 2022 ROCKVILLE, Md. , Sept. 27, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-...
RegeneRx Issues 2022 Letter To Stockholders
Update on Product Candidates, FDA Regulatory Strategy, Operations ROCKVILLE, Md. , Aug. 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinic...
RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis
ROCKVILLE, Md. , July 18, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair...
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259
ROCKVILLE, Md. , June 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair...
Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea
ROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regenerati...
RegeneRx Provides Regulatory Update Regarding RGN-259
ROCKVILLE, Md., March 2, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerat...
RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health
ROCKVILLE, Md., Feb. 11, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regenera...
Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury
ROCKVILLE, Md., Jan. 25, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regenera...
RegeneRx Publishes Regulatory Update on RGN-259
ROCKVILLE, Md., Jan. 12, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, rep...
RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022
ROCKVILLE, Md., Dec. 17, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerat...
RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome
ROCKVILLE, Md., Nov. 29, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerat...
Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting
ROCKVILLE, Md., Oct. 29, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerat...
Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis
ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerati...
New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease
ROCKVILLE, Md., Oct. 5, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerati...
RegeneRx Licensee Acquired by Korean Biopharmaceutical Group
ROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenera...
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerat...
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
ROCKVILLE, Md., July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerati...